Apnimed, Inc.

Lo que declaró Apnimed, Inc. el 8 de septiembre de 2026

Del propio 8-K de la empresa.

Conferencias de resultados

Apnimed, Inc. no tiene ninguna transcripción de conferencia de resultados disponible.

Lo que dijo la dirección

“This was a highly productive quarter for Apnimed as we continued to execute against our strategy, highlighted by the FDA’s acceptance of our NDA for AD109 (proposed proprietary name Oxnimbi), with a PDUFA target action date of February 28, 2027,”

Citado literalmente de la publicación, y mostrado solo cuando el informe lo atribuye a una persona con nombre.

Cómo reaccionó la cotización

Las publicaciones salen tras el cierre o antes de la apertura, así que el movimiento es el de la sesión siguiente.

A qué se dedica Apnimed, Inc.

Apnimed is a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases. We believe the introduction of once-nightly oral drugs has the potential to expand diagnosis and the reach of treatment for people with OSA. We believe that people with OSA would benefit from having multiple treatment options with differing mechanisms to more fully address the heterogeneity of OSA’s disease pathophysiology. Apnimed envisions a new era where novel oral therapies simplify intervention and expand the reach of diagnosis and treatment. Apnimed is advancing its product candidate, AD109 (proposed proprietary name Oxnimbi), which is designed to improve oxygenation in individuals living with OSA. We believe that Oxnimbi could become the catalyst for a new oral treatment paradigm for OSA that has been historically limited to devices or invasive surgeries. Learn more at apnimed.com or follow us on X and LinkedIn.

La propia descripción de la empresa, tal como aparece al pie de la publicación.